AMERISOURCEBERGEN
17.11.2022 14:31:38 CET | Business Wire | Press release
Alliance Healthcare, a part of global healthcare company AmerisourceBergen and a leading wholesaler of pharmaceutical products in Europe, and GIRP, the European Healthcare Distribution Association, convened policymakers and leaders across the healthcare and pharmaceutical industries today to discuss antimicrobial resistance (AMR), examine current response efforts and explore opportunities to collaborate on initiatives to combat the global public health issue.
The inaugural event featured remarks from members of the European Parliament, European Commission and organizations spearheading AMR response efforts, as well as panel discussions led by healthcare and pharmaceutical executives. Panelists and speakers covered a variety of topics, including how public policy can advance response efforts, strategies to increase awareness of AMR, actions healthcare providers are taking to combat resistance, and public-private partnerships to support the development of new antimicrobials. Professor Dame Sally Davies, UK Special Envoy on AMR and member of the UN Global Leaders Group on AMR, delivered a keynote address focused on mobilizing international efforts and driving a global response.
AMR, which occurs when a microorganism (bacteria, virus, fungi, parasite) develops the ability to resist the effects of a drug, is a significant global public health threat. The World Health Organization (WHO), U.S. Government and European Commission each have initiated action plans against AMR.
“Addressing an issue as complex and far-reaching as AMR requires public-private collaboration and coordination across multiple sectors,” said Gianluigi Tassone, President of Alliance Healthcare. “By hosting this event, we sought to bring together policymakers, leaders across the healthcare supply chain and those at the forefront of international response efforts to discuss current approaches, share best practices and identify opportunities in which we can work together to help address this issue.”
“As the EU outlined in its action plan, there is an urgent need for multi-sector collaboration, innovation and policy action to tackle AMR,” said Monika Derecque-Pois, Director General of GIRP. “While this event serves as an important step in bringing together leaders across different industries, it’s equally important we continue these conversations and build on the potential solutions discussed today to help drive meaningful, sustained change.”
During the provider-focused panel, leaders from the European Hospital and Healthcare Federation, Standing Committee of European Doctors, European Association of Hospital Pharmacists and Boots UK offered perspective on how healthcare systems across Europe are prepared to manage AMR. The panelists spoke to the actions needed to combat resistance, including infection prevention and control measures, and initiatives underway to educate patients on AMR. For example, Alphega Pharmacy, a pan-European network of independent pharmacists and a part of Alliance Healthcare, launched a campaign to drive awareness of AMR and provide patients with additional counseling and education on proper use of antibiotics.
Representatives from the AMR Action Fund, a public-private partnership investing in biotech companies that are developing antibiotics, and BEAM Alliance, a coalition of small and medium-sized biopharma companies in Europe involved in developing products to combat AMR, discussed current industry priorities, including innovative approaches to support the research and development of new antibiotics and sustainable models to improve access to new antibiotics, diagnostics and vaccines globally.
“AMR is a silent pandemic. No one player can solve it on their own – it demands a coordinated approach,” said Dame Sally. “By collaborating across sectors and countries, we can innovate to secure the future of modern medicine so that treatments can be used sustainably by all who need them.”
About AmerisourceBergen
AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. As a leading global healthcare company, with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies, and providers, we create unparalleled access, efficiency, and reliability for human and animal health. Our more than 43,000 global team members power our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 with more than $200 billion in annual revenue. Learn more at https://amerisourcebergen.com/.
European Healthcare Distribution Association (GIRP)
GIRP, the European Healthcare Distribution Association, is the umbrella organisation for full-service healthcare distributors in Europe. It represents the national associations of over 750 pharmaceutical wholesalers serving 34 European countries, as well as major international and pan-European healthcare distribution companies. GIRP members employ over 140,000 people and distribute around 15 billion packs of medicines as well as a wide range of healthcare products per year. As the vital link in healthcare, they are committed to developing and providing innovative and efficient healthcare products and services to improve health and wellbeing of patients across Europe. Learn more at girp.eu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005239/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Authorizes ZYN ULTRA Nicotine Pouches Following Scientific Review21.8.2026 21:11:00 CEST | Press release
Authorizations add selection of ZYN ULTRA products to PMI U.S.’s growing portfolio of better alternatives for legal-age adults who smoke or use traditional oral tobacco products Philip Morris International Inc. (NYSE: PM) today announces that the U.S. Food and Drug Administration (FDA) issued Marketing Granted Orders to PMI’s U.S. affiliate, Swedish Match USA, Inc., authorizing the marketing of 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. Additional 11mg variants remain under scientific review. Today’s action further enhances PMI’s leadership role in the smoke-free category. “We are delighted with the FDA’s decision to authorize a range of ZYN ULTRA products, which will build on ZYN’s position as America’s leading smoke-free product brand,” said Stacey Kennedy, PMI U.S. CEO. “We look forward to expanding our portfolio of better choices for the 45 million Americans who consume nicotine products.” ZYN ULTRA positions the brand to furth
58% of Consumers Say They Don't Care Whether a Product is a National Brand or Private Label. They Just Buy What They Need21.8.2026 12:00:00 CEST | Press release
New NIQ & World Data Lab report reveals how consumer polarization is redefining value, accelerating private label adoption, and reshaping competition on the shelf As fast-moving consumer goods (FMCG) prices rose 26% globally between 2021 and 2025, consumers have become more deliberate about where they save and where they spend. NielsenIQ (NYSE: NIQ) has released new findings showing that private label is no longer viewed simply as a lower-cost substitute, but as a credible competitor across value, mainstream, and premium segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260819950224/en/ Private label is no longer just a value play. The findings, published in NIQ’s latest report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, created in collaboration with World Data Lab, show how consumer polarization is redefining value and reshaping competition on the shelf. The report also draws on ins
Tanium Reappoints Co-Founder Orion Hindawi as CEO to Drive Next Chapter of Growth20.8.2026 21:10:00 CEST | Press release
Company to focus on deepening its Autonomous IT capabilities, further expanding AI offerings across its portfolio, and strengthening customer and partner engagement Tanium, a leader in Autonomous IT, today announced that Co-Founder and Executive Chairman Orion Hindawi has been appointed Chief Executive Officer, effective immediately. Dan Streetman is stepping down as CEO and as a member of the Board after leading Tanium for the last three years, during which time Tanium scaled its go-to-market operations and secured strong industry analyst recognition for innovation within the Tanium platform. Streetman will continue to advise Tanium as part of the transition and co-founder David Hindawi will return to the role of Chairman of the Board. With this foundation in place, this transition positions Tanium to deepen its Autonomous IT capabilities and further expand AI offerings across its portfolio and strengthen customer and partner engagement. The Hindawis co-founded Tanium in 2007 to build
PCI Energy Solutions to Join Mitsubishi Electric, Reinforcing Long-Term Commitment to Customers, Employees, and the Energy Industry20.8.2026 19:46:00 CEST | Press release
Mitsubishi Electric to retain PCI’s core management team and support continuity of operations, customer service, and product innovation PCI Energy Solutions ("PCI"), a leading U.S.-based provider of enterprise software for energy management and optimization, announced today that it has entered into a definitive agreement to be acquired by Mitsubishi Electric Corporation. The agreement was executed on August 20, 2026 (Japan Standard Time). The Transaction represents a strong endorsement of PCI's business, technology, employees, customer relationships and position in the energy industry. Mitsubishi Electric intends to retain PCI's core management team following completion of the Transaction, enabling PCI to preserve leadership continuity, industry expertise and its customer-focused operating model while benefiting from Mitsubishi Electric's global scale, complementary capabilities and long-term investment capacity. The agreement has been signed, but the Transaction has not yet closed. PC
Perma-Pipe Secures More Than $67 Million in New Orders in the Second Quarter of 202620.8.2026 19:02:00 CEST | Press release
Awards include significant Oil & Gas projects in MENA and Canada, as well as the Company's largest single leak detection project to date and continued growth at its new Ohio facility. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH), a global leader in engineered piping and corrosion protection solutions, today announced that the Company secured more than $67 million in new orders during the second quarter of fiscal 2026, representing strong demand across its strategically important end-markets and geographies. The orders further strengthen Perma-Pipe's backlog and provide increased visibility into future revenue growth. The Company's backlog remains well diversified across geographies, customers and end-markets. The Company continued to see strong demand across its core Oil & Gas and infrastructure markets, while also securing important new business in emerging applications, including advanced leak detection and monitoring solutions. During the quarter, Perma-Pipe secured sizabl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom